Donate during COVID-19
Our researchers at the Center for the Evaluation of Value and Risk in Health (CEVR), including CEVR Director Peter J. Neumann, ScD, frequently contribute their knowledge to a wide range of prestigious, peer-reviewed journals.
Butt T, Liu GG, Kim DD, Neumann PJ. Taking stock of cost-effectiveness analysis of healthcare in China. BMJ Global Health 2019;4(3):1–9. 31179038
Chambers JD, Panzer AD, Kim DD, Margaretos NM, Neumann PJ. Variation in US private health plans’ coverage of orphan drugs. The American Journal of Managed Care. 2019;25(10):508-512. 31622066
Chambers JD, Panzer AD, Pope EF, Graff JS, Neumann PJ. Little consistency in evidence cited by commercial plans for specialty drug coverage. Health Affairs 2019;38(11):1882–6. 31682500
Cohen JT, Silver MC, Ollendorf DA, Neumann PJ. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments? Value in Health 2019;22(12):1396–401. 31806196
Drummond MF, Neumann PJ, Sullivan SD, Fricke FU, Tunis S, Dabbous O, Toumi M. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value in Health 2019 (in press). 31198183
Emerson J, Bacon R, Kent A, Neumann PJ, Cohen JT. Publication of decision model source code: Attitudes of health economics authors. PharmacoEconomics 2019;:1–2. 31214898
Emerson J, Panzer A, Cohen JT, Chalkidou K, Teerawattananon Y, Sculpher M, Wilkinson T, Walker D, Neumann PJ, Kim DD. (2019) Adherence to the iDSI reference case among published cost-per-DALY averted studies. PLoS ONE 14(5): e0205633. 31042714
Garrison LP, Neumann PJ, Willke RJ. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy. Journal of Managed Care & Specialty Pharmacy 2019;25(11):1185–92. 31663458
Herman PM, Broten N, Lavelle TA, Sorbero ME, Coulter ID. Exploring the prevalence and construct validity of high-impact chronic pain across chronic low-back pain study samples. The Spine Journal 2019 (in press). 30885677
Herman PM, Broten N, Lavelle TA, Sorbero ME, Coulter ID. Healthcare Costs and Opioid Use Associated with High-Impact Chronic Spinal Pain in the United States. Spine 2019 (in press). 31373999
Hlávka JP, Lin PJ, Neumann PJ. Outcome measures for oncology alternative payment models: Practical considerations and recommendations. The American Journal of Managed Care 2019. 31860235
Kim DD, Cohen JT, Wong JB, Mohit B, Fendrick AM, Kent DM. Targeted incentive programs for lung cancer screening can improve population health and economic efficiency. Health Affairs 2019;38(1):60–7. 30615528
Kim DD, Guzauskas GF, Bennette CS, Basu A, Veenstra DL, Ramsey SD, Carlson JJ. Influence of modeling choices on value of information analysis: An empirical analysis from a real-world experiment. PharmacoEconomics 2019;:1–9. 31631254
Kim DD, Neumann PJ. "Comparative modeling to inform health policy decisions: A step forward," Annals of Internal Medicine Editorial," November 4, 2019. 31683277
Kim DD, Trikalinos TA, Wong JB. Leveraging cumulative network meta-analysis and value of information analysis to understand the evolving value of medical research. Medical Decision Making 2019;39(2):119–29. 30678537
Kim DD, Wilde PE, Michaud DS, Liu J, Lizewski L, Onopa J, Mozaffarian D, Zhang FF, Wong JB. Cost Effectiveness of Nutrition Policies on Processed Meat: Implications for Cancer Burden in the U.S. American Journal of Preventive Medicine 2019;57(5). 31564600
Lavelle TA, Messonnier M, Stokley S, et al. Use of a choice survey to identify adult, adolescent and parent preferences for vaccination in the United States. Journal of Patient-Reported Outcomes 2019;3(1). 31359289
Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. Parent preferences for health outcomes associated with autism spectrum disorders. PharmacoEconomics 2019;37(4):541–51. 30895565
Lin PJ, D'Cruz B, Leech AA, Neumann PJ, Aigbogun MS, Oberdhan D, Lavelle TA. Family and caregiver spillover Effects in cost‑utility analyses of alzheimer’s disease interventions. PharmacoEconomics 2019;37(3):1–12. 30903567
Neumann PJ. Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time. Value in Health 2019;22(9):975–6. 31511185
Wright DR, Saelens BE, Fontes A, Lavelle TA. Assessment of Parents’ Preferences for Incentives to Promote Engagement in Family-Based Childhood Obesity Treatment. JAMA Network Open 2019;2(3). 30924902
Chambers J, Pope E, Bungay K, Cohen JT, Ciarametaro M, Dubois R, Neumann PJ. A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. Value in Health 2018;21(4):400–6. 29680096
Chambers JD, Kim DD, Pope EF, Graff JS, Wilkinson CL, Neumann PJ. Specialty Drug Coverage Varies Across Commercial Health Plans In The US. Health Affairs 2018;37(7):1041–7. 29985695
Chambers JD, Pope EF, Wilkinson CL, Neumann PJ. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies. Journal of Managed Care & Specialty Pharmacy 2018;24(12):1240–6. 30479201
Garrison LP, Neumann PJ, Willke RJ, et al. A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report . Value in Health 2018;21(2):161–5. 29477394
Garrison LP, Pauly MV, Willke RJ, Neumann PJ. An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report . Value in Health 2018;21(2):124–30. 29477389
Goldman DP, Fillit H, Neumann P. Accelerating Alzheimers disease drug innovations from the research pipeline to patients. Alzheimers & Dementia 2018; 29680407
Kim DD, Arterburn DE, Sullivan SD, Basu A. Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes. Medical Care 2018;:1. 29762271
Kumar V, Cohen JT, Klaveren DV, Soeteman DI, Wong JB, Neumann PJ, Kent DM. Risk-Targeted Lung Cancer Screening. Annals of Internal Medicine 2018;168(3):161. 30083710
Ladin K, Emerson J, Berry K, Butt Z, Gordon EJ, Daniels N, Lavelle TA, Hanto DW. Excluding patients from transplant due to social support: Results from a national survey of transplant providers. American Journal of Transplantation 2018; 29878515
Lavelle TA, D’Cruz BN, Mohit B, Ungar WJ, Prosser LA, Tsiplova K, Monserrat VL, Lin PJ. Family spillover effects in pediatric cost-utility analyses. Applied Health Economics and Health Policy 2018; 30350218
Lavelle TA, Kent DM, Lundquist CM, Thorat T, Cohen JT, Wong JB, Olchanski N, Neumann PJ. Patient Variability Seldom Assessed in Cost-Effectiveness Studies. Medical Decision Making 2018; 29351053
Lavelle TA, Rose AJ, Timbie JW, Setodji CM, Wensky SG, Giuriceo KD, Friedberg MW, Malsberger R, Kahn KL. Utilization of health care services among Medicare beneficiaries who visit federally qualified health centers. BMC Health Services Research 2018;18(1). 29370837
Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value in Health 2018;21(7):759–61. 30005746
Lin P-J, Pope E, Zhou FL. Comorbidity Type and Health Care Costs in Type 2 Diabetes: A Retrospective Claims Database Analysis. Diabetes Therapy 2018; 30097994
Melnitchouk N, Soeteman DI, Davids, JS, Fields A, Cohen JT, Noubary F, Lukashenko A, Kolesnik OO, Freund KM. Colorectal cancer screening cost saving in Ukraine. PharmacoEconomics & Outcomes News 2018;805(1):11–. 29977160
Neumann PJ, Anderson JE, Panzer AD, Pope EF, D'Cruz BN, Kim DD, Cohen JT. Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. Gates Open Research 2018;2:5. 29431169
Neumann PJ, Cohen JT. QALYs in 2018—Advantages and Concerns. Jama 2018;319(24):2473. 29800152
Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE, Ganiats TG, Sanders GD. Future Directions for Cost-effectiveness Analyses in Health and Medicine. Medical Decision Making 2018;38:767-77. 30248277
Neumann PJ, Willke RJ, Garrison LP. A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report . Value in Health 2018;21(2):119–23. 29477388
Olchanski N, Hansen RN, Pope E, Fergie J, Goldstein M, Krilov LR, McLaurin KK, Nabrit-Stephens B, Oster G, Schaecher K, Shaya FT, Neumann PJ, Sullivan SD. Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open Forum Infectious Diseases 2018;5(3). 29516023
Olchanski N, Vest A, Rane P, Neumann PJ, DeNofrio D. Cost Comparison Across Heart Failure Patients With Reduced And Preserved Ejection Fractions: Analyses Of Inpatient Decompensated Heart Failure Admissions. Journal of the American College of Cardiology 2016;67(13):1469. 29657034
Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO8, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM. Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. British Journal of Haematology 2018;182(2):212–21. 29707774
Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science 2018;360(6386):278–9. 29674586
Thokala P, Ochalek J, Leech AA, Tong T. Cost-Effectiveness Thresholds: the Past, the Present and the Future. PharmacoEconomics 2018;36(5):509–22. 29427072
Thorat T, Neumann PJ, Chambers JD. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia. Journal of Managed Care & Specialty Pharmacy 2018;24(7):632–42. 29952709
Willke RJ, Neumann PJ, Garrison LP, Ramsey SD. Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report . Value in Health 2018;21(2):155–60. 29477393
Chambers JC, Weiner DE, Bliss SK, Neumann PJ. What can we learn from the US expanded end-stage renal disease bundle? Health Policy. 2013; (110):164-171. PMID: 23419419
Lerner D, Rodday AM, Cohen JT, Rogers WH. A Systematic Review of the Evidence Concerning the Economic Impact of Employee-Focused Health Promotion and Wellness Programs. J Occup Environ Med. 2013 Jan 2. [Epub ahead of print] PMID: 23287723
Lin PJ, Neumann PJ. The economics of mild cognitive impairment. Alzheimers and Dementia. 2013; (9):58–62. PMID: 23141385
Lin PJ, Fillit HM, Cohen JT, Neumann PJ. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer’s disease and related disorders. Alzheimer’s & Dementia 9 (2013) 30–38. PMID: 23305822
Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The Validity of Dependence as a Health Outcome Measure in Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2013 Mar 19. [Epub ahead of print] PMID: 23512996
Barshes NR, Chambers JD, Cohen JT, Belkin M. Cost Effectiveness in the contemporary management of critical limb ischemia with tissue loss. Journal of Vascular Surgery. 2012 Oct;56(4):1015-1024.PMID: 22854267
Barshes NR, Chambers JD, Cantor SB, Cohen J, Belkin M. A primer on cost-effectiveness analyses for vascular surgeons. Journal of Vascular Surgery. 2012 Jun;55(6):1794-800.PMID: 22608043
Cangelosi MJ, Bliss SK, Chang H, Dubois RW, Lerner D, Neumann PJ, Westrich K, Cohen JT. Imputing productivity gains from clinical trials. Journal of Occupational and Environmental Medicine.2012 Jul;54(7):826-33.PMID: 22796927
†Chambers JD, Morris S, Neumann PJ, Buxton MJ. Factors Predicting Medicare National Coverage. Medical Care. 2012 Mar;50(3):249-56.PMID: 22193418
Cohen JT, Marino RJ, Sacco P, Terrin N. Association between the Functional Independence Measure following spinal cord injury and long term outcomes. Spinal Cord. 2012 Oct;50(10):728-33.PMID: 22641254
Cohen JT, Miller G, Roehrig C. Cost-Effectiveness of Cardiovascular Disease Spending. Journal of the American College of Cardiology. 2012;60(20):2123-2124.PMID: 22193418
Doshi JA, Hodgkins P, Kahle J, Sikirika V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ. Economic Impact of Childhood and Adult Attention-Deficit. Hyperactivity Disorder in the United States. Journal of the American Academy of Child & Adolescent Psychiatry. 2012 October; 51(10): 990-1002.PMID: 23021476
Drummond M, Neumann PJ, Jonsson B, Luce B, Schwartz JS, Siebert U, Sullivan SD. Can we reliably benchmark health technology assessment organizations? International Journal of Technology Assessment in Health Care. 28:2(2012):159-165.PMID: 22559758
Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB. Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension. Journal of the American College of Cardiology 2012; 60(14):1271-7.PMID: 22981547
Gray GM, Cohen JT. Rethink Chemical Risk Assessments. Nature. 2012 Sep 6;489(7414):27-8.PMID: 22955594
Hammerman A, Feder-Bubis P, Greenberg D. Financial risk-sharing in updating the national list of health services in Israel: stakeholders' perceived interests. Value in Health. 2012 Jul-Aug;15(5):737-42.PMID: 22867784
Leslie LK, Cohen JT, Newburger JW, Alexander ME, Wong JB, Sherwin ED, Rodday AM, Parsons SK, Triedman JK. Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. Circulation. 2012 May 29;125(21):2621-9.PMID: 22556340
Luce BR, Drummond MF, Dubois RW, et al. Principles for planning and conducting comparative effectiveness research. Journal of Comparative Effectiveness Research. 2012; 1(5): 431-440.
Lin PJ, Neumann PJ. The economics of mild cognitive impairment. Alzheimers and Dementia. 2012;1-5.PMID: 23141385
Neumann PJ, Bliss SK. FDA actions against health economic promotions, 2002-2011. Value in Health.2012 Sep;15(6):948-53.PMID: 22999146
Neumann PJ, Bliss SK, Chambers JD. Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Affairs. 2012 Apr;31(4):700-8.PMID: 22492886
Neumann PJ, Chambers JD. Medicare's enduring struggle to define 'reasonable and necessary' care. New England Journal of Medicine. 2012 October 31.367(19):1775-1777.
Neumann PJ, What we talk about when we talk about health care costs. New England Journal of Medicine. 2012 Feb;366(7):585-86.PMID: 22335735
Neumann, PJ, Cohen, JT, Hammitt, JK, Concannon, TW, Auerbach, HR, Fang, CH, Kent, DM. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Economics. 2012 Mar;21(3):238-51.PMID: 22271512
O’Grady MJ, John P, Winn A. Substantial Medicare savings may result if insurers cover ‘artificial pancreas’ sooner for diabetes patients. Health Affairs. 2012 Aug;31(8):1822-9.PMID: 22869661
Otero HJ, Chambers JD, Bresnahan BW, Kamae MS, Yucel KE, Neumann PJ. Medicare's National Coverage Determinations in Diagnostic Radiology: Examining Evidence and Setting Limits. Academic Radiology. 2012 Sep;19(9):1060-5.PMID: 22748382
Rodday AM, Triedman JK, Alexander ME, Cohen JT, Ip S, Newburger JW, Parsons SK, Trikalinos TA, Wong JB, Leslie LK. Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic Children: A meta-analysis. Pediatrics. 2012 Apr;129(4):e999-1010.PMID: 22392183
*Thorat T, Cangelosi M, Neumann PJ. Skills of the trade: The Tufts cost-effectiveness analysis registry. Journal of Benefit-Cost Analysis. 2012 Feb;3(1):1-7.
Wilson AW, Neumann PJ, The cost-effectiveness of biopharmaceuticals: A look at the evidence. MAbs. 2012 Mar 1;4(2).PMID: 22377753
* Publication used data from CEA Registry
† Publication used data from NCD database
Buxton, MJ, Chambers, JD. What values do the public want their health care systems to use in evaluating technologies? European Journal of Health Economics. Published online May 15, 2011. PMID: 21573933
Cangelosi, MJ, Auerbach, HR, Cohen, JT. A clinical and economic evaluation of enteral nutrition. Current Medical Research Opinion. 2011 Feb;27(2):413-22. Epub 2010 Dec 30. PMID: 21192760
†Chambers JD, Morris S, Neumann PJ, Buxton M. Factors predicting Medicare national coverage: An empirical analysis. Medical Care. 2011 Dec 28. PMID: 22193418
Chambers J, Neumann PJ. Listening to Provenge — what a costly cancer treatment says about Medicare policy on new technology. New England Journal of Medicine. 2011 May 5;364(18):1687-9. PMID: 21470004
Gazelle GS, Kessler L, Lee DW, McGinn T, Menzin J, Neumann PJ, van Amerongen D, White LA. The Working Group on Comparative Effectiveness Research for Imaging. A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness research. Radiology 2011 Dec;261(3):692-698. PMID: 22095993
*Greenberg, D., Neumann, PJ. Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions? Expert Reviews 2011. Published online 2011. PMID: 21351863
*Kamae MS, Kamae I, Cohen JT, Neumann PJ. Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS. Journal of Medical Economics 2011. Published online 2011. PMID: 21332273
Maciejewski ML, Wang VW, Grabowski DC, Lin PJ. Early evidence on the quality of care provided by special needs plans. Medical Care 2011;49(10):891-896. PMID: 21572358
Neumann PJ, Chambers J, Simon F, Meckley L. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Affairs. 2011 Dec; 30(4): 2329-2337. PMID:22147861
Neumann, PJ, Cohen, JT, Hammitt, JK, Concannon, TW, Auerbach, HR, Fang, CH, Kent, DM. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Economics 2011. Published online Dec. 28, 2010. PMID: 21190163
Neumann PJ. What’s next for QALYs. Journal of the American Medical Association 2011 May; 305(17):1806-1807. PMID: 21540426
Neumann PJ, Lin PJ, Hughes TE. FDAMA Section 114: Current Uses and Opportunities for Comparative Effectiveness Research. Pharmacoeconomics 2011 July; 29(8):687-692. PMID: 21540426
Yang Z, Zhang K, Lin PJ, Clevenger CK, Atherly A. A longitudinal analysis of the lifetime cost of dementia. Health Services Research. 2011 Dec 15. PMID: 22171532.
* Publication used data from CEA Registry
† Publication used data from NCD database
Brixner, DI, Holtorf, AP, Neumann, PJ, Malone, DC, Watkins, JB Standardizing quality assessment of observational studies for decision making in health care. J Manag Care Pharm. 2009;15:(3)275-283. PubMed: 19326959
Berry SR, Bell CM, Ubel PA et al. Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated with New Cancer Drugs. J Clin Oncol 2010 PubMed: 20697077
Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010; 96:179-190.
†Chambers JD, Neumann PJ, Buxton MJ. Does Medicare Have an Implicit Cost-Effectiveness Threshold? Medical Decision Making 2010. PubMed: 20551473
Chambers JD, Neumann PJ. US healthcare reform: implications for health economics and outcomes research. Expert Review Pharmacoeconomic Outcomes Research 2010; 10(3):215-216. PubMed: 20545583
Cohen JT, Neumann PJ. Using decision analysis to better evaluate pediatric clinical guidelines. Health Affairs. 2008 Sep-Oct;27(5):1467-75. PubMed: 18780939
Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. New England Journal of Medicine. 2008 Feb(7);358:661-663. PubMed: 18272889
Cohen JT. Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. Expert Review Pharmacoeconomic Outcomes Research 2010; 10(5):595-603. PubMed
Fillit H, Cummings J, Neumann PJ, McLaughin T. Salvatore P, Leibman C. Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer’s disease. The Journal of Nutrition Health & Aging 2010; 14(8):640-647.c
Freeman RB, Cohen JT. Transplantation risks and the real world: what does 'high risk' really mean? Am J Transplant 2009; 9(1):23-30. PubMed: 19067660
Gabbay E, Calvo-Broce J, Meyer KB, Trikalinos TA, Cohen J, Kent DM. The empirical basics for determinations of medical futility. General Internal Medicine 2010; 25(10):1083-10839.
Garrison LP, Jr., Neumann PJ, Radensky P, Walcoff SD. A flexible approach to evidentiary standards for comparative effectiveness research. Health Affairs (Millwood) 2010; 29(10):1812-1817.
*Greenberg D, Earle CC, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility studies in oncology. Journal of the National Cancer Institute 2010;102(2):82-88. PubMed: 20056956
*Greenberg D, Rosen AB, Wacht O, Palmer JA, Neumann PJ. A bibliometric review of cost-effectiveness analysis in the economic and medical literature, 1976-2007. Medical Decision Making. Published online March 2010. PubMed: 20228286
Jacobson PD, Neumann PJ. A framework to measure the value of public health services. Health Services Research. In press.
Kozminski MA, Neumann PJ, Nadler ES, Jankovic A, Ubel PA. How long and how well: oncologists’ attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments. Medical Decision Making. 2010. Published online, November 24, 2010.
Lin PJ, Kaufer DI, Maciejewski ML, Ganguly R, Paul JE, Biddle AK. An examination of Alzheimer’s case definitions using Medicare claims and survey data. Alzheimers and Dementia. PubMed: 20434960
Lin PJ, Maciejewski ML, Paul JE, Biddle AK. Risk adjustment for Medicare beneficiaries with Alzheimer’s disease and related dementias. American Journal of Managed Care 2010;16(3):191-198. PubMed: 20225914
Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med. PubMed: 19954941
Luce BR, Drummond M, Jonsson B et al. EBM, HTA, and CER: clearing the confusion. Milbank Q 2010; 88(2):256-276 PubMed: 20579285
McLaughin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan MJ, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Yaakov. Dependence as a unifying contruct in defining Alzheimer’s disease severity. Alzheimer’s and Dimentia 2010; 6(1):482-493.
Meckley LM, Neumann PJ. Personalized medicine: Factors influencing reimbursement. Health Policy 2010;94:91-100. PubMed: 19815307
*Neumann PJ, Auerbach HR, Cohen JT, Greenberg D. “Low-value” services in value-based insurance design. American Journal of Managed Care 2010;16(4):280-286. PubMed: 20394464
Neumann PJ, Drummond MF, Jönsson B, Luce B, Schwartz JS, Siebert U, Sullivan SD. Are key principles for improved health technology assessment supported and used by HTA organizations? International Journal of Technology Assessment in Health Care 2010 Jan;21(1):71-78. PubMed: 20059783
†Neumann PJ, Tunis SR. Medicare and medical technology – the growing demand for relevant outcomes. New England Journal of Medicine 2010;362(5):377-379. PubMed: 20089955
*Neumann PJ, Palmer JA, Fang CH, Nadler E, Ubel PA. Struggling with expensive new cancer therapies: A national survey of oncologists. Health Affairs 2010 Jan;29(1):196-202. PubMed: 20048377
Neumann PJ. American exceptionalism and American health care: Implications for the U.S. debate on cost-effectiveness analysis. Office of Health Economics Briefing. 2009;47. http://www.ohe.org/page/publications/publication.cfm?catid=35&itemid=636&archive=0
Neumann PJ. Are mAbs different? A commentary on Cohen and Wilson. MaBs. 2009;1(1):29-30. http://www.landesbioscience.com/journals/mabs/article/7193/
Neumann PJ. Costing and perspective in published cost-effectiveness analyses. Medical Care. 2009; 47(7s1):s28-s32. Pubmed: 19536023
Neumann PJ. Lessons for health technology assessment: It is not only about the evidence. Value in Health 2009; 12(s2):s45-s48. PubMed: 19523184
Neumann PJ. Whatever happened to FDAMA Section 114? A look back after 10 years. Value Health 2009; 12(2):189-190. PubMed: 18657100
Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity, and methodological improvement. Pharmacoeconomics. In press.
Neumann PJ, Jacobson PD, Palmer JA. Measuring the value of public health systems: The disconnect between health economists and public health practitioners. American Journal of Public Health. 2008 Dec;98(12):2173-2180. PubMed:
Neumann PJ, Kamae MS, Palmer JA. Medicare’s national coverage decisions for technologies, 1999-2007. Health Affairs. 2008 Nov:27(6):1620-1631. PubMed:
Neumann PJ, Weinstein M.C. Legislating against use of cost-effectiveness information. New England Journal of Medecine 2010; 363(16):1495-1497. PubMed
*Otero HJ, Rybicki FJ, Greenberg D, Mitsouras D, Mendoza JA, Neumann PJ. Cost-Effective Diagnostic Cardiovascular Imaging: When Does It Provide Good Value for the Money? International Journal of Cardiovascular Imaging 2010. PubMed:
Otero HJ, Rybicki FJ, Greenberg D, Neumann PJ. 20 years of cost-effectiveness analysis in medical imaging: Are we improving?. Radiology. 2008 Dec;249(3):917-925. PubMed:
Palmer JA, Timm AR, Neumann PJ. Drug Company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999. Journal of Managed Care Pharmacy. 2008;14(8):749-55. PubMed:
Rothberg MB, Cohen JT, Lindenauer P, Maselli J, Auerbach AD. Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality. Health Affairs (Millwood) 2010; 29(8):1523-1531.
Shaya FT, Yan X, Lin PJ, Simoni-Wastia L, Bron M, Baran R, Donner T. US Trends in Glycemic Control, Treatment, and Comorbidity Burden in Patients With Diabetes. Journal of Clinical Hypertension 2010;12(10):826–832.
It's time to use a name that is trusted locally and revered nationally.
The one that has been by our side throughout our long journey.
Every person here understands
that we are not just taking care of the child.
We are taking care of the childhood.